Angiotensin receptor blockers (ARBs) vs. angiotensin-converting enzyme inhibitors (ACEi) treatment in hypertension: what is the evidence to date?

Professor Bryan Williams explores the role of ARBs and ACEi in antihypertensive therapy and explores the relative merits of using an ARB or ACEi.


Angiotensin receptor blockers (ARBs) vs. angiotensin-converting enzyme inhibitors (ACEi) treatment in hypertension: what is the evidence to date? In this first part, Professor Williams explores why ARBs and ACEi are the foundation of antihypertensive therapy before going on to compare the relative merits of each approach to blocking the RAS system.


Angiotensin receptor blockers (ARBs) vs. angiotensin-converting enzyme inhibitors (ACEi) treatment in hypertension: what is the evidence to date? In part 2, Professor Williams addresses whether there are any differences in the safety and persistence of ARBs and ACEi and what challenges are faced when both treatment classes are combined.